Login to Your Account


GSK to Shine Light on Raw Clinical Trial Data

By Marie Powers
Staff Writer

Wednesday, October 17, 2012
GlaxoSmithKline plc (GSK) took extraordinary steps toward data transparency last week, disclosing plans to accelerate its "open innovation" approach to R&D by allowing researchers access to detailed patient-level data underlying clinical trials both in approved medicines and failed investigational compounds.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription